- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
World Vaccine Congress Lyon 2008
Summary
6 Oct 2008-9 Oct 2008 — Lyon, France
Qualify the investment trends that are invigorating the vaccine market.
Contact details
Caroline Thoresen email: caroline.thoresen@terrapinn.com phone: +44 (0)20 7092 1230
Venue
Congress — 6 Oct Mon-13:00 9 Oct 2008
• Qualify the investment trends that are invigorating the vaccine market
• Focus on the strategic and competitive factors that are dictating the resurgence in vaccines
• Evaluate the business opportunities within vaccines
• Align your product portfolio capability with operational strategy
• Develop relationships within the wider public, private and global health circles
• Four congress days and 13 exclusive streams giving you more choice than ever before
URL of online registration form
Pricing: Register before 25th of July and save up to €573! We also offer a 50% discount for academia, government and non-profit organisations. For more information on pricing and discounts please contact caroline.thoresen@terrapinn.com
Topics include:
• Vaccine policy, pipelines and progress
• Engaging vaccines for competitive advantage
• Global health governance
• Novel vaccine introduction
• Influenza preparedness and evolution
• Clinical trials and tribulations
• Vaccine production and manufacture
• A new frontier for therapeutic vaccines
• Adjuvants and delivery systems
• Vaccine technology innovation
• Vaccine safety evaluation
• Why invest in vaccines? Why now?
• Partnerships and IP management
• Future investment outlook
• Vaccine funding expectations
• Cancer vaccines and immunotherapy
• Cancer vaccine technologies
Key note speakers include:
• Didier Hoch, President, sanofi pasteur MSD, and President, European Vaccine Manufacturers
• Gerd Zettlmeissl, CEO, Intercell
• Dr Allan Jarvis, Senior Vice President, Corporate Development, sanofi pasteur
• Dr Douglas Holtzman, Senior Program Officer, Infectious Disease, Global Health Program, Bill & Melinda Gates Foundation
• Michel Zaffran, Senior Adviser to Director of the Department of Immunisation, Vaccines and Biologicals, WHO, and Senior Adviser and Project Optimize Director, WHO-PATH Collaboration
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us